Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H14N2O.ClH |
| Molecular Weight | 298.767 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=C2NC3=C(C=C(O)C=C3)C2=C(C)C4=CN=CC=C14
InChI
InChIKey=DLDKVFOKLGPVBT-UHFFFAOYSA-N
InChI=1S/C17H14N2O.ClH/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17;/h3-8,19-20H,1-2H3;1H
| Molecular Formula | C17H14N2O |
| Molecular Weight | 262.3059 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. | 2013-02-15 |
|
| Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases. | 2012-05-21 |
|
| Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl. | 2009-09-03 |
|
| Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2. | 2008-09 |
|
| Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. | 2006-12 |
|
| Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. | 2006-09 |
|
| Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography. | 2005-08 |
|
| The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. | 2004-11-15 |
|
| 9-hydroxyellipticine and derivatives as chemotherapy agents. | 2003-03 |
|
| Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents. | 2003-01-01 |
|
| Cardioprotective effects of 9-hydroxyellipticine on ischemia and reperfusion in isolated rat heart. | 2002-05 |
|
| 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein. | 2001-11-29 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 12:15:36 GMT 2025
by
admin
on
Wed Apr 02 12:15:36 GMT 2025
|
| Record UNII |
6KBD4FD43H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20966614
Created by
admin on Wed Apr 02 12:15:36 GMT 2025 , Edited by admin on Wed Apr 02 12:15:36 GMT 2025
|
PRIMARY | |||
|
52238-35-4
Created by
admin on Wed Apr 02 12:15:36 GMT 2025 , Edited by admin on Wed Apr 02 12:15:36 GMT 2025
|
PRIMARY | |||
|
264136
Created by
admin on Wed Apr 02 12:15:36 GMT 2025 , Edited by admin on Wed Apr 02 12:15:36 GMT 2025
|
PRIMARY | |||
|
6KBD4FD43H
Created by
admin on Wed Apr 02 12:15:36 GMT 2025 , Edited by admin on Wed Apr 02 12:15:36 GMT 2025
|
PRIMARY | |||
|
148569
Created by
admin on Wed Apr 02 12:15:36 GMT 2025 , Edited by admin on Wed Apr 02 12:15:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
